Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.
作者信息
Ludwig Heinz, San-Miguel Jesús, Munshi Nikhil, Sonneveld Pieter, Mateos María-Victoria, Moreau Philippe, Terpos Evangelos
机构信息
First Department of Medicine, Clinic Ottakring, Wilhelminen Cancer Research Institute, Vienna, Austria.
CIMA, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain.
出版信息
Am J Hematol. 2021 Aug 1;96(8):896-900. doi: 10.1002/ajh.26263. Epub 2021 Jun 21.
Abstract
摘要
相似文献
1
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.多发性骨髓瘤患者的新冠病毒疫苗接种：关注免疫反应。
Am J Hematol. 2021 Aug 1;96(8):896-900. doi: 10.1002/ajh.26263. Epub 2021 Jun 21.
2
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
3
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.接受B细胞定向疗法的淋巴瘤患者对新冠疫苗接种的体液免疫反应受损。
Blood. 2021 Sep 2;138(9):811-814. doi: 10.1182/blood.2021012443.
4
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.与完全接种 BNT162b2 疫苗的患者相比，感染 COVID-19 的骨髓瘤患者具有更高的抗体反应。
Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.
5
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
6
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
7
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.血液透析患者中 SARS-CoV-2 mRNA 疫苗的细胞和体液免疫原性。
EBioMedicine. 2021 Aug;70:103524. doi: 10.1016/j.ebiom.2021.103524. Epub 2021 Aug 12.
8
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.多发性骨髓瘤和华氏巨球蛋白血症无症状前驱期患者对SARS-CoV-2疫苗的反应减弱。
Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9.
9
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.常见变异性免疫缺陷患者中抗 SARS-CoV-2 疫苗的免疫原性。
J Clin Immunol. 2022 Feb;42(2):240-252. doi: 10.1007/s10875-021-01174-5. Epub 2021 Nov 17.
10
The long road.漫长的道路。
Science. 2021 Feb 19;371(6531):768-772. doi: 10.1126/science.371.6531.768.
引用本文的文献
1
Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease.2022 年 12 月以来北京奥密克戎波期间浆细胞异常患者的 COVID-19 特征和结局：国家血液系统疾病临床医学研究中心的一项回顾性研究。
Ann Hematol. 2023 Oct;102(10):2857-2864. doi: 10.1007/s00277-023-05350-y. Epub 2023 Jul 12.
2
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
3
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy.第二剂BNT162b2加强针可恢复多发性骨髓瘤患者的新冠病毒体液免疫反应，但接受抗BCMA治疗的患者除外。
Hemasphere. 2022 Jul 29;6(8):e764. doi: 10.1097/HS9.0000000000000764. eCollection 2022 Aug.
4
Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19.肿瘤血液病患者接种一剂抗新冠病毒疫苗后的早期细胞和体液反应
J Clin Med. 2022 May 16;11(10):2803. doi: 10.3390/jcm11102803.
5
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.COVID-19 mRNA 疫苗在患有淋巴恶性肿瘤或抗 CD20 抗体治疗的患者中的应用：一项系统评价和荟萃分析。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e691-e707. doi: 10.1016/j.clml.2022.03.012. Epub 2022 Mar 28.
6
Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection.自然感染后接受自体干细胞移植的肿瘤血液病患者对新冠病毒产生强烈的细胞免疫反应而非体液免疫反应。
J Clin Med. 2022 Apr 11;11(8):2137. doi: 10.3390/jcm11082137.
7
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤的不良事件管理与支持性治疗
Cancers (Basel). 2021 Oct 4;13(19):4978. doi: 10.3390/cancers13194978.
8
Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals.在 COVID-19 康复个体中，mRNA COVID-19 疫苗可快速、强烈和持久地诱导抗体反应。
JCI Insight. 2021 Oct 22;6(20):e151477. doi: 10.1172/jci.insight.151477.
9
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.COVID-19 疫苗接种后骨髓瘤患者的中和抗体反应高度依赖于抗骨髓瘤治疗的类型。
Blood Cancer J. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3.
本文引用的文献
1
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
2
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
3
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.巴西玛瑙斯市 P.1 型 SARS-CoV-2 谱系的基因组学和流行病学研究。
Science. 2021 May 21;372(6544):815-821. doi: 10.1126/science.abh2644. Epub 2021 Apr 14.
4
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.接种BNT162b2 mRNA疫苗后，医护人员和八旬老人针对新冠病毒的年龄和性别依赖性抗体反应。
Am J Hematol. 2021 Jul 1;96(7):E257-E259. doi: 10.1002/ajh.26185. Epub 2021 Apr 24.
5
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.恢复期血清和疫苗血清对 SARS-CoV-2 B.1.1.7 变异株的中和能力降低。
Cell. 2021 Apr 15;184(8):2201-2211.e7. doi: 10.1016/j.cell.2021.02.033. Epub 2021 Feb 18.
6
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
7
Neutralizing Activity of BNT162b2-Elicited Serum.BNT162b2诱导血清的中和活性
N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.
8
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对单剂量BNT162b2疫苗体液和T细胞反应的影响
Lancet. 2021 Mar 27;397(10280):1178-1181. doi: 10.1016/S0140-6736(21)00502-X. Epub 2021 Feb 25.
9
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma.多发性骨髓瘤患者的新型冠状病毒2型疫苗
Hemasphere. 2021 Feb 17;5(3):e547. doi: 10.1097/HS9.0000000000000547. eCollection 2021 Mar.
10
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.无症状和轻症 SARS-CoV-2 感染患者中和抗体和 T 细胞反应的不一致性。
Sci Immunol. 2020 Dec 23;5(54). doi: 10.1126/sciimmunol.abf3698.
Zotero 插件